Woodline Partners LP Has $376,000 Stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Woodline Partners LP reduced its holdings in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 44.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 19,005 shares of the company's stock after selling 15,024 shares during the quarter. Woodline Partners LP's holdings in Kiniksa Pharmaceuticals were worth $376,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Teacher Retirement System of Texas raised its position in shares of Kiniksa Pharmaceuticals by 7.1% during the 4th quarter. Teacher Retirement System of Texas now owns 10,862 shares of the company's stock valued at $215,000 after acquiring an additional 719 shares in the last quarter. Martingale Asset Management L P raised its position in shares of Kiniksa Pharmaceuticals by 1.9% during the 4th quarter. Martingale Asset Management L P now owns 49,360 shares of the company's stock valued at $976,000 after acquiring an additional 900 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its position in shares of Kiniksa Pharmaceuticals by 12.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,814 shares of the company's stock valued at $174,000 after acquiring an additional 1,004 shares in the last quarter. MetLife Investment Management LLC raised its position in shares of Kiniksa Pharmaceuticals by 6.3% during the 4th quarter. MetLife Investment Management LLC now owns 23,095 shares of the company's stock valued at $457,000 after acquiring an additional 1,374 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Kiniksa Pharmaceuticals by 6.7% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,841 shares of the company's stock valued at $432,000 after acquiring an additional 1,380 shares in the last quarter. 53.95% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Kiniksa Pharmaceuticals

In other news, CAO Michael R. Megna sold 9,051 shares of the company's stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $22.45, for a total transaction of $203,194.95. Following the completion of the sale, the chief accounting officer now directly owns 26,528 shares of the company's stock, valued at $595,553.60. This represents a 25.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Ross Moat sold 18,259 shares of the firm's stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $20.29, for a total value of $370,475.11. Following the sale, the insider now owns 9,415 shares of the company's stock, valued at $191,030.35. The trade was a 65.98% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 329,910 shares of company stock valued at $8,336,038 over the last 90 days. 54.57% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

KNSA has been the topic of several research reports. Citigroup initiated coverage on Kiniksa Pharmaceuticals in a research report on Thursday, March 13th. They set a "buy" rating and a $40.00 price target on the stock. Wedbush reissued an "outperform" rating and set a $34.00 price target on shares of Kiniksa Pharmaceuticals in a research report on Wednesday, April 16th. Finally, Jefferies Financial Group upped their price target on Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the company a "buy" rating in a research report on Tuesday, April 29th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Kiniksa Pharmaceuticals presently has a consensus rating of "Buy" and an average price target of $38.80.

Kiniksa Pharmaceuticals Stock Up 0.9%

NASDAQ KNSA traded up $0.25 during trading hours on Friday, hitting $27.43. The company had a trading volume of 543,644 shares, compared to its average volume of 492,782. Kiniksa Pharmaceuticals, Ltd. has a fifty-two week low of $17.38 and a fifty-two week high of $28.56. The business has a fifty day simple moving average of $23.62 and a 200-day simple moving average of $21.64. The firm has a market cap of $2.00 billion, a P/E ratio of -195.91 and a beta of 0.07.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The company reported $0.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.09. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The company had revenue of $137.79 million during the quarter, compared to analysts' expectations of $128.35 million. During the same quarter in the prior year, the business posted ($0.25) earnings per share. The company's revenue for the quarter was up 72.5% compared to the same quarter last year. Equities analysts forecast that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current fiscal year.

Kiniksa Pharmaceuticals Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.